Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Otorhinolaryngologic Diseases

ClinicalTrials.gov lists 7,551 trials for Otorhinolaryngologic Diseases or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 112.

MeSH D010038 Otorhinolaryngologic Diseases C09
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 382 Phase 1/2 Phase 1/2 200 Phase 2 Phase 2 936 Phase 2/3 Phase 2/3 103 Phase 3 Phase 3 742 Phase 4 Phase 4 428 Not applicable Not applicable 3,039 Observational Observational 1,708 Phase 1 Phase 1 382 Phase 1/2 Phase 1/2 200 Phase 2 Phase 2 936 Phase 2/3 Phase 2/3 103 Phase 3 Phase 3 742 Phase 4 Phase 4 428 Not applicable Not applicable 3,039 Observational Observational 1,708

Trials per phase (log scale)

2 more sections with rows

63 of the 7,551 trials are tagged with Otorhinolaryngologic Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Otorhinolaryngologic Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Otorhinolaryngologic Diseases trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 29 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 525

1991: 1 trials (Observational 1) 1992: 1 trials (Observational 1) 1993: 3 trials (Observational 1, Phase 3 2) 1994: 3 trials (Phase 3 3) 1995: 5 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 1) 1996: 13 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 2, Phase 1 1) 1997: 11 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 3, Phase 1/2 2, Phase 1 1) 1998: 17 trials (Observational 5, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 5, Phase 1 1) 1999: 25 trials (Observational 6, Not applicable 5, Phase 3 3, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 3) 2000: 28 trials (Observational 6, Not applicable 6, Phase 4 2, Phase 3 6, Phase 2 3, Phase 1/2 3, Phase 1 2) 2001: 38 trials (Observational 8, Not applicable 7, Phase 4 3, Phase 3 7, Phase 2/3 1, Phase 2 6, Phase 1/2 2, Phase 1 4) 2002: 52 trials (Observational 7, Not applicable 5, Phase 4 17, Phase 3 12, Phase 2/3 1, Phase 2 7, Phase 1 3) 2003: 69 trials (Observational 7, Not applicable 8, Phase 4 16, Phase 3 24, Phase 2 9, Phase 1/2 3, Phase 1 2) 2004: 77 trials (Observational 9, Not applicable 12, Phase 4 13, Phase 3 23, Phase 2/3 3, Phase 2 12, Phase 1/2 1, Phase 1 4) 2005: 137 trials (Observational 29, Not applicable 19, Phase 4 19, Phase 3 40, Phase 2/3 1, Phase 2 19, Phase 1/2 1, Phase 1 9) 2006: 173 trials (Observational 33, Not applicable 31, Phase 4 26, Phase 3 36, Phase 2/3 3, Phase 2 27, Phase 1/2 5, Phase 1 12) 2007: 195 trials (Observational 37, Not applicable 38, Phase 4 32, Phase 3 26, Phase 2/3 3, Phase 2 38, Phase 1/2 3, Phase 1 18) 2008: 200 trials (Observational 37, Not applicable 48, Phase 4 26, Phase 3 23, Phase 2/3 4, Phase 2 39, Phase 1/2 7, Phase 1 16) 2009: 200 trials (Observational 50, Not applicable 45, Phase 4 17, Phase 3 32, Phase 2/3 5, Phase 2 29, Phase 1/2 6, Phase 1 16) 2010: 230 trials (Observational 62, Not applicable 59, Phase 4 13, Phase 3 22, Phase 2/3 6, Phase 2 46, Phase 1/2 4, Phase 1 18) 2011: 218 trials (Observational 46, Not applicable 56, Phase 4 12, Phase 3 39, Phase 2/3 4, Phase 2 36, Phase 1/2 9, Phase 1 16) 2012: 244 trials (Observational 44, Not applicable 94, Phase 4 12, Phase 3 29, Phase 2/3 1, Phase 2 39, Phase 1/2 12, Phase 1 13) 2013: 266 trials (Observational 52, Not applicable 83, Phase 4 24, Phase 3 38, Phase 2/3 7, Phase 2 38, Phase 1/2 10, Phase 1 14) 2014: 268 trials (Observational 48, Not applicable 115, Phase 4 17, Phase 3 28, Phase 2/3 3, Phase 2 38, Phase 1/2 4, Phase 1 15) 2015: 283 trials (Other 1, Observational 51, Not applicable 127, Phase 4 21, Phase 3 28, Phase 2/3 4, Phase 2 25, Phase 1/2 13, Phase 1 13) 2016: 324 trials (Other 2, Observational 70, Not applicable 135, Phase 4 17, Phase 3 33, Phase 2/3 6, Phase 2 39, Phase 1/2 8, Phase 1 14) 2017: 331 trials (Other 1, Observational 97, Not applicable 137, Phase 4 8, Phase 3 25, Phase 2/3 2, Phase 2 38, Phase 1/2 9, Phase 1 14) 2018: 419 trials (Observational 93, Not applicable 208, Phase 4 21, Phase 3 31, Phase 2/3 4, Phase 2 35, Phase 1/2 10, Phase 1 17) 2019: 404 trials (Other 1, Observational 106, Not applicable 191, Phase 4 14, Phase 3 17, Phase 2/3 7, Phase 2 44, Phase 1/2 10, Phase 1 14) 2020: 381 trials (Observational 103, Not applicable 164, Phase 4 12, Phase 3 31, Phase 2/3 3, Phase 2 42, Phase 1/2 6, Phase 1 20) 2021: 494 trials (Other 1, Observational 131, Not applicable 238, Phase 4 16, Phase 3 28, Phase 2/3 8, Phase 2 49, Phase 1/2 7, Phase 1 16) 2022: 498 trials (Observational 108, Not applicable 254, Phase 4 11, Phase 3 28, Phase 2/3 5, Phase 2 58, Phase 1/2 10, Phase 1 24) 2023: 469 trials (Observational 124, Not applicable 218, Phase 4 9, Phase 3 29, Phase 2/3 7, Phase 2 42, Phase 1/2 14, Phase 1 26) 2024: 525 trials (Other 1, Observational 127, Not applicable 263, Phase 4 13, Phase 3 30, Phase 2/3 6, Phase 2 55, Phase 1/2 13, Phase 1 17) 2025: 465 trials (Other 1, Observational 101, Not applicable 239, Phase 4 13, Phase 3 33, Phase 2/3 5, Phase 2 47, Phase 1/2 9, Phase 1 17)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 412
2025 465
2024 525
2023 469
2022 498
2021 494
2020 381
2019 404
2018 419
2017 331

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 490 trials starting in 2026 and about 490 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 695 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 4,432 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Otorhinolaryngologic Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 382
Phase 1/2 200
Phase 2 936
Phase 2/3 103
Phase 3 742
Phase 4 428
Not applicable 3,039
Observational 1,708
Expanded access 5
Unknown 8

How many Otorhinolaryngologic Diseases trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 418
Recruiting 875
Enrolling by invitation 66
Active, not recruiting 248
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Otorhinolaryngologic Diseases trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 112
Cochlear 84
Sonova AG 81
Organon and Co 77
National Cancer Institute (NCI) 54

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Otorhinolaryngologic Diseases? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
OPN-375 45
CETUXIMAB 38
PEMBROLIZUMAB 36
Montelukast 33

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cisplatin 1 190
Gemcitabine/Gemzar 60
Dexamethasone/Dexamethasone acetate 56
Docetetaxel 43
Radiation Therapy 40

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Otorhinolaryngologic Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,264 64
Gastroenteritis 1,102 12
Dehydration 1,061 47
Bronchiolitis 1,032 7
Asthmatic crisis 403 2

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Otorhinolaryngologic Diseases? (46)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Mind-Body Therapies in the Management of Otolaryngologic Disease: A State-of-the-Art Review of Randomized Controlled Trials. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2024 Yes
Safety Recommendations for Evaluation and Surgery of the Head and Neck During the COVID-19 Pandemic. JAMA otolaryngology-- head & neck surgery 2020 Yes
Practical insights for paediatric otolaryngology surgical cases and performing microlaryngobronchoscopy during the COVID-19 pandemic. International journal of pediatric otorhinolaryngology 2020 Yes
Patient Safety and Quality for Office-Based Procedures in Otolaryngology. Otolaryngologic clinics of North America 2019 Yes
Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Annals of the rheumatic diseases 2019 Yes

Showing 5 of 46 publications.

Start your 14-day trial Email me all 46 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages